FindTrial
Sign In

A Randomized, Double-Blind, Placebo-Controlled Trial for the Myocardial Protection of Trimetazidine in Elderly Coronary Artery Disease Patients Undergoing Non-cardiac Surgery

A Randomized, Double-Blind, Placebo-Controlled Trial for the Myocardial Protection of Trimetazidine in Elderly Coronary Artery Disease Patients Undergoing Non-cardiac Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025018
Enrollment
Unknown
Registered
2019-08-07
Start date
2014-03-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery patients

Interventions

Experimental group:trimetazidine
Control group:Nil

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male or female patients aged over 60 years, meet with the diagnosis criteria of coronary artery disease published by American Heart Association; electrocardiogram suggesting myocardial ischemia, patients with independent risk factors such as obesity, smoking, hypertension, diabetes, etc.; American Society of Anesthesiologists (ASA) Grade II to III, cardiac function (NYHA) II to III; willing to sign informed consent to complete the test process.

Exclusion criteria

Exclusion criteria: Any cases that were undergoing emergency surgery or cardiac surgery, or with the complication of congenital heart disease, rheumatic heart disease, myocardiopathy, left ventricular hypertrophy, Valvular Disease, with a history of myocardial infarction in the previous 3 months, hepatic or renal failure, mental disorders.

Design outcomes

Primary

MeasureTime frame
MCT, LDH, cTnI;—

Contacts

Public ContactZhongliang Dai

Shenzhen People's Hospital

daizhongliang@jnu.edu.cn+86 13530756996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026